EGFR and prostate cancer: In this respect, a pharmacophore directed against the epidermal growth factor receptor (EGFR) may be a promising hybridization partner, as the EGFR is also overexpressed and/or overactive in various solid tumors, including hepatocellular and prostate cancer [6,7].